Table 3.

Adverse Events of Systemic Treatments: Others (Lenvatinib =4, Ramucirumab =4, Atezolizumab =2, Pembrolizumab =1)

Variables	Total=138	Sorafenib=72	Nivolumab=33	Atezo+Bev=22	Others=11	P-value
ALT elevation	39 (28.3%)	22 (15.9%)	7 (21.2%)	5 (22.7%)	5 (45.4%)	0.402
Anorexia	47 (34.1%)	30 (41.7%)	8 (24.2%)	5 (22.7%)	4 (36.4%)	0.207
AST elevation	83 (60.1%)	42 (58.3%)	18 (54.5%)	13 (59.1%)	10 (90.9%)	0.181
Confusion	16 (11.6%)	9 (12.5%)	4 (12.1%)	1 (4.5%)	2 (18.2%)	0.660
Constipation	23 (16.7%)	14 (19.4%)	6 (18.2%)	1 (4.5%)	2 (18.2%)	0.423
Creatinine elevation	17 (12.3%)	8 (11.1%)	7 (21.2%)	1 (4.5%)	1 (9.1%)	0.278
Diarrhea	20 (14.5%)	15 (20.8%)	4 (12.1%)	1 (4.5%)	0 (0%)	0.107
Fatigue	42 (30.4%)	25 (34.7%)	11 (33.3%)	2 (9.1%)	4 (36.4%)	0.129
Itching	18 (13.0%)	9 (12.5%)	6 (18.2%)	2 (9.1%)	1 (9.1%)	0.743